CYTEK BIOSCIENCES INC (CTKB) Stock Price, Quote, News and Overview
NASDAQ:CTKB - Nasdaq - US23285D1090 - Common Stock - Currency: USD
CTKB Quote, Performance and Key Statistics
3.86
+0.16 (+4.32%)
The current stock price of CTKB is 3.86 USD. In the past month the price increased by 3.76%. In the past year, price decreased by -37.94%.
CTKB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.34 | 159.89B | ||
| DHR | DANAHER CORP | 26.72 | 142.41B | ||
| A | AGILENT TECHNOLOGIES INC | 20.46 | 30.97B | ||
| IQV | IQVIA HOLDINGS INC | 13.78 | 27.06B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 27.19 | 22.92B | ||
| WAT | WATERS CORP | 29.52 | 20.85B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.82 | 15.18B | ||
| ILMN | ILLUMINA INC | 31.79 | 12.33B | ||
| ICLR | ICON PLC | 10.42 | 11.80B | ||
| RVTY | REVVITY INC | 19.06 | 11.29B | ||
| TEM | TEMPUS AI INC | N/A | 9.87B | ||
| QGEN | QIAGEN N.V. | 19.52 | 9.32B |
Related stock screener links
About CTKB
Company Profile
Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 648 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
Company Info
CYTEK BIOSCIENCES INC
47215 Lakeview Boulevard
Fremont CALIFORNIA US
Employees: 645
Company Website: https://cytekbio.com
Investor Relations: https://investors.cytekbio.com/
Phone: 18779229835
CYTEK BIOSCIENCES INC / CTKB FAQ
What is the stock price of CYTEK BIOSCIENCES INC today?
The current stock price of CTKB is 3.86 USD. The price increased by 4.32% in the last trading session.
What is the ticker symbol for CYTEK BIOSCIENCES INC stock?
The exchange symbol of CYTEK BIOSCIENCES INC is CTKB and it is listed on the Nasdaq exchange.
On which exchange is CTKB stock listed?
CTKB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CYTEK BIOSCIENCES INC stock?
12 analysts have analysed CTKB and the average price target is 6.83 USD. This implies a price increase of 77.05% is expected in the next year compared to the current price of 3.86. Check the CYTEK BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CYTEK BIOSCIENCES INC worth?
CYTEK BIOSCIENCES INC (CTKB) has a market capitalization of 494.47M USD. This makes CTKB a Small Cap stock.
How many employees does CYTEK BIOSCIENCES INC have?
CYTEK BIOSCIENCES INC (CTKB) currently has 645 employees.
What are the support and resistance levels for CYTEK BIOSCIENCES INC (CTKB) stock?
CYTEK BIOSCIENCES INC (CTKB) has a resistance level at 3.87. Check the full technical report for a detailed analysis of CTKB support and resistance levels.
Is CYTEK BIOSCIENCES INC (CTKB) expected to grow?
The Revenue of CYTEK BIOSCIENCES INC (CTKB) is expected to grow by 0.72% in the next year. Check the estimates tab for more information on the CTKB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CYTEK BIOSCIENCES INC (CTKB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CTKB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CTKB, evaluating the profitability, health, valuation and growth aspects
- CYTEK BIOSCIENCES INC (CTKB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYTEK BIOSCIENCES INC (CTKB) Sales and EPS estimates to see what analysts future expectations are.
- CYTEK BIOSCIENCES INC (CTKB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYTEK BIOSCIENCES INC (CTKB) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYTEK BIOSCIENCES INC (CTKB) Stock Chart to make your own analysis
- CYTEK BIOSCIENCES INC (CTKB) Latest news and press-releases to stay up to date.
Does CYTEK BIOSCIENCES INC (CTKB) stock pay dividends?
CTKB does not pay a dividend.
When does CYTEK BIOSCIENCES INC (CTKB) report earnings?
CYTEK BIOSCIENCES INC (CTKB) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of CYTEK BIOSCIENCES INC (CTKB)?
CYTEK BIOSCIENCES INC (CTKB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.05).
What is the Short Interest ratio of CYTEK BIOSCIENCES INC (CTKB) stock?
The outstanding short interest for CYTEK BIOSCIENCES INC (CTKB) is 3.55% of its float. Check the ownership tab for more information on the CTKB short interest.
CTKB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CTKB. When comparing the yearly performance of all stocks, CTKB is a bad performer in the overall market: 85.75% of all stocks are doing better.
CTKB Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to CTKB. No worries on liquidiy or solvency for CTKB as it has an excellent financial health rating, but there are worries on the profitability.
CTKB Financial Highlights
Over the last trailing twelve months CTKB reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS decreased by -202.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.21% | ||
| ROE | -1.52% | ||
| Debt/Equity | 0 |
CTKB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to CTKB. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -2% and a revenue growth 0.72% for CTKB